Specialised Therapeutics

Singapore – September 20, 2026 -- Specialised Therapeutics (ST) has expanded its partnership with Incyte Biosciences International to commercialise, distribute, and register ruxolitinib cream, marketed as Opzelura, in Australia.

ST gains rights to market Opzelura for vitiligo and atopic dermatitis in Australia

Under the expanded agreement, Incyte will continue to develop and manufacture ruxolitinib cream, a topical Janus kinase (JAK) inhibitor, while ST takes on regulatory submissions, medical affairs, marketing, and distribution across the Australian market. The drug is approved in the U.S. and European Union for treating non-segmental vitiligo and mild-to-moderate atopic dermatitis in patients who do not respond adequately to standard topical therapies.